Vyvgart Expansion Vyvgart's label expansion broadens eligible patient populations in autoimmune neurology, creating increased demand opportunities across myasthenia gravis and CIDP. Focused BD outreach to neurology clinics, specialty pharmacies, and payers can accelerate uptake and drive formulary access.

Pipeline Momentum A busy slate of pipeline readouts and a broad antibody portfolio offer multiple entry points for partnerships, licensing deals, and co-development with other biotechs and pharma. Leverage these assets to present a diversified growth story to customers and investors.

Academic Partnerships The Immunology Innovation Program channels collaborations with leading academic researchers, enabling early target identification and potential joint development opportunities. This creates a pathway for research institutions to engage in sponsored programs and for larger deals with collaborators.

Global Immunology Focus Argenx positions itself as a global specialist in autoimmune diseases with antibody-based medicines, presenting cross-indication sales opportunities across neurology, rheumatology, and dermatology. Potential strategic partnerships with pharma seeking immune-targeted therapies could accelerate market access.

Financial Confidence With a credible revenue trajectory and a strong emphasis on expanding the Vyvgart franchise alongside the pipeline, Argenx offers a solid platform for sales discussions with health systems and payers. Leverage this position to pursue pricing strategies, value-based agreements, and broader access partnerships.